TVTX

Business Context and Reporting Period

Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter ended March 31, 2025
Business Overview: Travere is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its primary commercial product is FILSPARI (sparsentan) for IgA nephropathy (IgAN), which received full FDA approval in September 2024. The company also markets Thiola/Thiola EC for cystinuria and is developing sparsentan for FSGS and pegtibatinase for homocystinuria (HCU).

Key Financial Metrics

Liquidity: As of March 31, 2025, the company held approximately $322.2 million in cash and marketable securities. Management believes this is sufficient to fund operations beyond the next 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 98% year-over-year, driven primarily by a 182% increase in FILSPARI sales ($55.9M vs. $19.8M) and a $4.5M increase in license/collaboration revenue. The latter included a $3.8M sale of active pharmaceutical ingredients to CSL Vifor.
• Improved Loss Profile: Net loss narrowed significantly to $41.2M from $136.1M in Q1 2024. This improvement was aided by the absence of a $65.2M in-process research and development (IPR&D) charge recognized in Q1 2024 related to the pegtibatinase acquisition.
• Operating Expenses: Total operating expenses decreased by $56.2M to $124.4M. R&D expenses declined $2.5M due to reduced external service provider costs as Phase 3 programs advance. SG&A increased $8.6M due to commercialization spend for FILSPARI and higher intangible asset amortization.
• Inventory: Sales of FILSPARI continue to consist primarily of "zero-cost" inventory (expensed prior to approval), resulting in a high gross margin profile that is not expected to persist once this inventory is depleted (approx. $1.9M remaining).

Guidance, Outlook, and Risks

Management Commentary & Outlook

• FILSPARI (IgAN): Full FDA approval was granted in September 2024. The company is pursuing a REMS modification to reduce liver monitoring frequency, with a PDUFA date of August 28, 2025. European standard marketing authorization was granted in April 2025, triggering a $17.5M milestone payment.
• FILSPARI (FSGS): An sNDA was submitted to the FDA in March 2025 seeking priority review for traditional approval. The company expects a filing decision in Q2 2025.
• Pegtibatinase (HCU): Enrollment in the Phase 3 HARMONY Study was voluntarily paused in September 2024 due to manufacturing scale-up issues. The company anticipates restarting enrollment in 2026.
• Debt Maturity: The company has $68.9M in 2.5% Convertible Senior Notes due September 15, 2025, which must be repaid, refinanced, or converted.

Risks and Contingencies

• Manufacturing Delays: The pause in the pegtibatinase Phase 3 trial highlights risks in scaling manufacturing for commercial supply.
• Regulatory Uncertainty: While an sNDA for FSGS was submitted, the FDA has not yet accepted it for review, and approval is not guaranteed.
• Generic Competition: Thiola and Thiola EC face competition from multiple generic versions, impacting sales stability.
• Capital Requirements: Future funding needs depend on clinical trial outcomes, regulatory approvals, and the ability to refinance the 2025 Notes.

Investor Verification Checklist

• Debt Refinancing: Verify the company's plan and ability to refinance or repay the $68.9M convertible notes maturing in September 2025.
• FSGS Regulatory Path: Monitor the FDA's acceptance of the sNDA for FSGS and the timeline for priority review.
• Pegtibatinase Restart: Track progress on manufacturing scale-up improvements and the confirmed timeline for restarting the HARMONY Study enrollment.
• Zero-Cost Inventory: Assess the remaining duration of the high-margin period driven by zero-cost FILSPARI inventory and the projected impact on future gross margins.
• European Milestones: Confirm receipt of the $17.5M regulatory milestone payment from CSL Vifor following the April 2025 standard marketing authorization.